Skip to main content
EXELExelixis, Inc.Buy Wait6.3·$65.11

Exelixis (EXEL) Q2 2026 earnings — TrendMatrix coverage

BEAT+2.7% vs estimateEPS $0.91 vs $0.89 estCurrent verdict Buy (Wait) 6.3/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q2 2026

Key numbers

Adjusted EPS
$0.91
Estimate
$0.89
Surprise
+2.7%
Revenue (period 2026-07-03)
$628.7M
Score today
6.3/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Exelixis (EXEL) beat the $0.89 estimate with adjusted EPS of $0.91 — a modest 2.7% upside surprise.

Current read · as of 2026-10-27

Where TrendMatrix's rating stands now

TrendMatrix currently rates EXEL Buy (Wait) at 6.3/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +2.7% surprise compares with a +12.9% four-quarter average. Next scheduled report: 2026-10-29.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=9.2 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Product: cabozantinib
  • Analyst target reached - limited upside remaining
  • Near 52-week high (0.7% away)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$65.11
Entry target
$63.28
Stop
$60.22

The stock trades at 20.5× trailing but 15.2× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 83 — a level conventionally read as overbought; gains at these levels often lean on momentum.

Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.

Healthcare context

EXEL at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$16.13B
P/E (fwd)
15.2
P/E (ttm)
20.5
52-week range
$36.00–$65.59
Off 52-week high
0.7%
RSI (14)
83
Volume vs avg
0.73×
Score today
6.3/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › EXEL › Earnings › Q2 2026 earnings